Cross Q&A: The Memorial Sloan-Kettering Mavericks
The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Outcome Determination for Adolescents and Young Adults with ALL
Xiaoli Mi, MD, presents data from a paper in Blood on the determination of outcomes for adolescents and young adults with ALL.
Pediatric-Inspired Chemotherapy Incorporating Pegaspargase in Adults with Ph-ALL
Varun Narendra, MD, describes a clinical trial that studied whether pediatric-inspired ALL regimens could be used in older adults with Philadelphia chromosome–positive ALL.
A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study
Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.
Cross Q&A: Team Moffitt Marrowvingians
The Memorial Sloan Kettering team gets the opportunity to question the clinical trial data presented by the H. Lee Moffitt team.
Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists
Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.
HyperCVAD in Frontline ALL
Nikesh Shah, MD, explains a key trial evaluating the efficacy and toxicity of hyper-CVAD in acute lymphocytic leukemia (ALL).
Use of Inotuzumab for ALL in the Frontline Setting
Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.
Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks
Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.
